Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2717-2724

  Pieper, Stephanie ^a   Kolve, Hedwig ^a   Gumbinger, Hans G ^a   Goletz, Grazyna ^a   Würthwein, Gudrun ^a   Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer; Children; Drug monitoring; Mycoses; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; VORICONAZOLE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONCENTRATION LOSS; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; INSOMNIA; INVASIVE FUNGAL DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA AND VOMITING; PHOTOPHOBIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; PLASMA; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84867645709     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks258     Document Type: Article

References (38)

1. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500.
2. European Medicines Agency. Vfend: EPAR - Product Information (last updated 21/03/2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Inform ation/human/000387/WC500049756.pdf (27 May 2012, date last accessed).
3. US FDA. Label Information for VFEND, NDA no. 021266, Highlights of Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s033,0212 67s037,021630s024lbl.pdf (27 May 2012, date last accessed).
4. Driscoll TA, Frangoul H, Nemecek ER et al. Pharmacokinetics and safety of intravenous voriconazole to oral switch in immunocompromised adolescents compared to adults. Antimicrob Agents Chemother 2011; 55: 5780-9.
5. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.
6. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-44.
7. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8.
8. Lat A, Thompson GR III. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4: 43-53.
9. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
10. Miyakis S, Van Hal SJ, Ray J et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2009; 16: 927-33.
11. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5.
12. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-6.
13. Trifilio SM, Yarnold PR, Scheetz MH et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53: 1793-6.
14. Pennick GJ, Clark M, Sutton DA et al. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348-50.
15. US Department of Health and Human Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. 2009. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009 -09-15_QuickReference_ 5x7.pdf (27 May 2012, date last accessed).
16. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
17. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
18. Kolve H, Ahlke E, Fegeler W et al. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009; 64: 383-7.
19. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
20. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
21. Andes D, Marchillo K, Stamstad T et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-9.
22. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
23. Tan K, Brayshaw N, Tomaszewski K et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-43.
24. Ueda K, Nannya Y, Kumano K et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592-9.
25. Imhof A, Schaer DJ, Schanz U et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739-42.
26. Zonios DI, Gea-Banacloche J, Childs R et al. Hallucinations during voriconazole therapy. Clin Infect Dis 2008; 47: e7-10.
27. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
28. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8.
29. Neely M, Rushing T, Kovacs A et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36.
30. Walsh TJ, Driscoll T, Milligan PA et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54: 4116-23.
31. Driscoll TA, Yu LC, Frangoul H et al. Pharmacokinetics and safety of intravenous voriconazole to oral switch in immunocompromised children compared to adults. Antimicrob Agents Chemother 2011; 55: 5770-9.
32. ClinicalTrials.gov. A Study to Evaluate the Safety of Voriconazole as Treatment of Invasive Aspergillosis (Fungal Infection) and Other Rare Molds in Children. http://clinicaltrials.gov/ct2/show/NCT00836875?term= Voriconazole+AND+Children&rank=7 (28 May 2012, date last accessed).
33. ClinicalTrials.gov. A Study of the Safety, Tolerability and Effectiveness of Voriconazole for the Treatment of Serious Candida Infection and Candida Infection of the Throat in Pediatric Patients. http://clinicaltrials. Therapeutic drug monitoring of voriconazole 2723 JAC gov/ct2/show/NCT01092832?term=Voriconazole+AND+Children&rank=9 (28 May 2012, date last accessed).
34. Soler-Palacin P, Frick MA, Martin-Nalda A et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2012; 67: 700-706.
35. Michael C, Bierbach U, Frenzel K et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010; 54: 3225-3232.
36. Bruggemann RJ, van der Linden JW, Verweij PE et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 2010; 30: 533-534.
37. Gerin M, Mahlaoui N, Elie C et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit 2011; 33: 464-466.
38. Molina JR, Serrano J, Sanchez-Garcia J et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marro Transplant 2012; 47: 562-567.